Melanoma patients showed intracranial responses when they received both a BRAF and MEK inhibitor.
All articles by Alexander M. Castellino
Intracranial and extracranial responses were provided with combination immunotherapy with nivolumab and ipilimumab, for patients with melanoma and brain metastases.
Publish Date
Talimogene laherparepvec along with ipilimumab improves the overall response rate over just ipilimumab among patients with unresected, advanced melanoma.
Publish Date
-
Latest News Your top articles for Monday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses